HC Wainwright Reaffirms "Buy" Rating for SOPHiA GENETICS (NASDAQ:SOPH)

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $14.00 target price on the stock. HC Wainwright's price target would suggest a potential upside of 88.93% from the company's previous close.

A number of other equities research analysts have also recently commented on the stock. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. BTIG Research upped their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $10.00.

SOPHiA GENETICS Stock Performance

Shares of SOPH opened at $7.41 on Monday. The business has a 50-day simple moving average of $7.91 and a two-hundred day simple moving average of $6.17. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS has a 52 week low of $3.75 and a 52 week high of $8.98. The stock has a market cap of $621.62 million, a price-to-earnings ratio of -6.44 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, analysts expect that SOPHiA GENETICS will post -0.77 EPS for the current year.

Insider Buying and Selling

In related news, insider Well Van sold 6,168 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.12, for a total transaction of $50,084.16. Following the sale, the insider owned 332,716 shares in the company, valued at approximately $2,701,653.92. This represents a 1.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 5,284 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.12, for a total transaction of $42,906.08. Following the completion of the sale, the chief technology officer directly owned 166,887 shares in the company, valued at approximately $1,355,122.44. This represents a 3.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 282,543 shares of company stock valued at $2,130,026 in the last three months. Corporate insiders own 4.88% of the company's stock.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently made changes to their positions in the business. First Dallas Securities Inc. purchased a new stake in SOPHiA GENETICS in the 1st quarter valued at about $50,000. Royal Bank of Canada grew its stake in SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. AXQ Capital LP bought a new position in SOPHiA GENETICS in the 2nd quarter worth about $119,000. Silverberg Bernstein Capital Management LLC increased its position in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock worth $257,000 after acquiring an additional 4,155 shares during the period. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the second quarter worth approximately $567,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.